靶向接种与疫苗耐久性对南非痘蛋白HIV疫苗方案的人群影响和成本效果至关重要
研究使用基于个体的随机网络传播模型,模拟南非2027年起痘蛋白HIV疫苗方案在不同靶向与治疗预防假设下的人群影响和成本效果。结果显示,在补接种覆盖率60%时,该部分有效疫苗至2047年可预防最多941,000例(15.6%)新感染;靶向高发病率年龄组可预防最多697,000例(11.5%)。若实现治疗扩大,接种在每10年系列总成本低于385美元和62美元时具有成本效果。
要点
- 部分有效且免疫力快速衰减的疫苗可减少HIV感染,但不能消除HIV作为撒哈拉以南非洲公共卫生优先事项。
- 靶向最高HIV发病率年龄组接种预期最有效。
- 接种引入应与HIV预防创新并行,并研究交付成本、可行性和更高效持久产品。
核心结论
- 部分有效、免疫力快速衰减的疫苗可帮助预防HIV感染,但无法使HIV在撒哈拉以南非洲作为公共卫生优先事项被消除。
- 靶向最高HIV发病率年龄组接种预期最有效。
- 接种引入应与持续HIV预防创新并行,包括研究交付成本、可行性及更高效持久产品。
研究设计与样本
- 使用基于个体的详细随机网络疾病传播模型,校准至HIV疫情。
- 模拟南非2027年起接种规划,假设痘蛋白方案基础系列5剂,首剂后24个月累计效力达50%,每两年加强针维持10年耐久效力。
- 模拟不同疫苗靶向及HIV治疗和预防假设下的接种规划。
主要发现
- 补接种覆盖率60%时,假设当前抗逆转录病毒治疗趋势,2027至2047年可预防最多941,000例(15.6%)新感染。
- 靶向最高发病率年龄组可预防最多697,000例(11.5%)感染。
- 若实现治疗扩大,每10年系列总成本低于385美元和62美元时接种具有成本效果(成本效果阈值分别为5,691美元和750美元)。
临床怎么用
- 接种规划应优先靶向最高HIV发病率年龄组以最大化人群影响。
- 引入接种应与持续HIV预防创新并行,并研究交付成本与可行性。
局限性
- 结果基于模型模拟和特定假设,需等待HVTN 702试验结果验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RV144 is to date the only HIV vaccine trial to demonstrate efficacy, albeit rapidly waning over time. The HVTN 702 trial is currently evaluating in South Africa a similar vaccine formulation to that of RV144 for subtype C HIV with additional boosters (pox-protein regimen). Using a detailed stochastic individual-based network model of disease transmission calibrated to the HIV epidemic, we investigate population-level impact and maximum cost of an HIV vaccine to remain cost-effective. METHODS: Consistent with the original pox-protein regimen, we model a primary series of five vaccinations meeting the goal of 50% cumulative efficacy 24 months after the first dose and include two-yearly boosters that maintain durable efficacy over 10 years. We simulate vaccination programs in South Africa starting in 2027 under various vaccine targeting and HIV treatment and prevention assumptions. RESULTS: Our analysis shows that this partially effective vaccine could prevent, at catch-up vaccination with 60% coverage, up to 941,000 (15.6%) new infections between 2027 and 2047 assuming current trends of antiretroviral treatment. An impact of up to 697,000 (11.5%) infections prevented could be achieved by targeting age cohorts of highest incidence. Economic evaluation indicates that, if treatment scale-up was achieved, vaccination could be cost-effective at a total cost of less than $385 and $62 per 10-year series (cost-effectiveness thresholds of $5,691 and $750). CONCLUSIONS: While a partially effective, rapidly waning vaccine could help to prevent HIV infections, it will not eliminate HIV as a public health priority in sub-Saharan Africa. Vaccination is expected to be most effective under targeted delivery to age groups of highest HIV incidence. Awaiting results of trial, the introduction of vaccination should go in parallel with continued innovation in HIV prevention, including studies to determine the costs of delivery and feasibility and further research into products with greater efficacy and durability.
引用
- Selinger C, Bershteyn A, Dimitrov DT, et al. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. Vaccine. 2019. PMID: 30890385. doi:10.1016/j.vaccine.2019.02.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。